---
document_datetime: 2023-09-21 20:45:56
document_pages: 35
document_pathfilename: www.ema.europa.eu/en/documents/assessment-report/abiraterone-krka-epar-public-assessment-report_en.pdf
document_name: abiraterone-krka-epar-public-assessment-report_en.pdf
version: success
processing_time: 26.2887714
conversion_datetime: 2025-12-30 09:45:18.459339
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
<!-- image -->

22 April 2021 EMA/653711/2021 Committee for Medicinal Products for Human Use (CHMP)

## Assessment report

## Abiraterone Krka

International non-proprietary name: abiraterone acetate

Procedure No. EMEA/H/C/005649/0000

## Note

Assessment report as adopted by the CHMP with all information of a commercially confidential nature deleted.

<!-- image -->

<div style=\"page-break-after: always\"></div>

## Table of contents

| 1. Background information on the procedure ..............................................5                                     |                                                                                                       |
|--------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------|
| 1.1. Submission of the dossier......................................................................................5          |                                                                                                       |
| 1.2. Steps taken for the assessment of the product.........................................................6                   |                                                                                                       |
| 2. Scientific discussion                                                                                                       | ................................................................................7                     |
| 2.1. Introduction.........................................................................................................7    |                                                                                                       |
| 2.2. Quality aspects                                                                                                           | ....................................................................................................8 |
| 2.2.1. Introduction......................................................................................................8     |                                                                                                       |
| 2.2.2. Active substance                                                                                                        | ...............................................................................................8      |
| General information                                                                                                            | ....................................................................................................8 |
| Manufacture, characterisation and process controls.........................................................9                   |                                                                                                       |
| Specification...............................................................................................................9  |                                                                                                       |
| Stability...................................................................................................................10 |                                                                                                       |
| 2.2.3. Finished medicinal product................................................................................10            |                                                                                                       |
| Description of the product and Pharmaceutical development                                                                      | ..........................................10                                                          |
| Manufacture of the product and process controls ..........................................................12                   |                                                                                                       |
| Product specification                                                                                                          | .................................................................................................12   |
| Stability of the product                                                                                                       | ..............................................................................................13      |
| Adventitious agents...................................................................................................14       |                                                                                                       |
| 2.2.4. Discussion on chemical, and pharmaceutical aspects............................................14                        |                                                                                                       |
| 2.2.5. Conclusions on the chemical, pharmaceutical and biological aspects                                                      | ......................14                                                                              |
| 2.2.6. Recommendation for future quality development.................................................14                        |                                                                                                       |
| 2.3. Non-clinical aspects                                                                                                      | ............................................................................................15        |
| 2.3.1. Introduction....................................................................................................15      |                                                                                                       |
| 2.3.2. Ecotoxicity/environmental risk assessment                                                                               | .........................................................15                                           |
| 2.3.3. Discussion on non-clinical aspects......................................................................15              |                                                                                                       |
| 2.3.4. Conclusion on the non-clinical aspects................................................................16                |                                                                                                       |
| 2.4. Clinical aspects                                                                                                          | ..................................................................................................16  |
| 2.4.1. Introduction....................................................................................................16      |                                                                                                       |
| 2.4.2. Pharmacokinetics.............................................................................................17         |                                                                                                       |
| 2.4.3. Pharmacodynamics..........................................................................................27            |                                                                                                       |
| 2.4.4. Post marketing experience................................................................................30             |                                                                                                       |
| 2.4.5. Discussion on clinical aspects                                                                                          | ............................................................................30                        |
| 2.4.6. Conclusions on clinical aspects                                                                                         | ..........................................................................32                          |
| 2.5. Risk management plan........................................................................................32            |                                                                                                       |
| 2.6. Pharmacovigilance..............................................................................................33         |                                                                                                       |
| 2.7. Product information                                                                                                       | ............................................................................................33        |
| 2.7.1. User consultation.............................................................................................33        |                                                                                                       |
| 3. Benefit-risk balance                                                                                                        | ..............................................................................33                      |
| 4. Recommendation...................................................................................34                         |                                                                                                       |

<div style=\"page-break-after: always\"></div>

## List of abbreviations

ADT

Androgen deprivation therapy

AE

Adverse event

ALT

Alanine aminotransferase

ANOVA

Analysis of variance

AP

Applicant's Part (or Open Part) of ASMF

API

Active Pharmaceutical Ingredient

AR

Assessment Report

ASM

Active Substance Manufacturer

ASMF

Active Substance Master File = Drug Master File

AST

Aspartate aminotransferase

AUC

Area under the curve

BEQ

Bioequivalence

CI

Confidence interval

Cmax

Maximum measured analyte concentration over the sampling period

CoA

Certificate of Analysis

CRF

Case report form

CRS

Chemical Reference Substance (official standard)

CS

Clinically significant

CV

Coefficient of variation

CYP

Cytochrome P450

DAD

Diode-array

DHEA

Dehydroepiandrosterone

EMA

European Medicines Agency

EU

European Union

FDA

Food and Drug Administration

GCP

Good Clinical Practice

GI

Gastrointestinal

HDPE

High-density polyethylene

HPLC

High Performance Liquid Chromatography

ICF

Informed consent form

ICH

International conference on harmonisation

ICH

International Council for Harmonisation

ICP-MS

Inductively coupled plasma mass spectrometry

IMP

Investigational medicinal product

IPC

In-process control

IR

Infrared

IRB

Institutional review board

Kel

Elimination rate constant

LDPE

Low-density polyethylene

LHRH

Luteinising hormone releasing hormone

LOD

Limit of Detection

LOQ

Limit of Quantification

LoQ

List of Questions

<div style=\"page-break-after: always\"></div>

| LQCT      | Last quantifiable concentration time                                        |
|-----------|-----------------------------------------------------------------------------|
| LSM       | Least-squares mean                                                          |
| MAH       | Marketing Authorisation holder                                              |
| mCRPC     | metastatic castration resistant prostate cancer                             |
| mHSPC     | metastatic hormone sensitive prostate cancer                                |
| MS        | Mass Spectrometry                                                           |
| ND        | Not detected                                                                |
| NLT       | Not less than                                                               |
| NMT       | Not more than                                                               |
| PE        | Polyethylene                                                                |
| PET       | Polyethylene terephthalate                                                  |
| Ph. Eur.  | European Pharmacopoeia                                                      |
| PK:       | Pharmacokinetic                                                             |
| PL        | Patient Leaflet                                                             |
| PMRI      | Pharma Medica Research Inc.                                                 |
| PSA       | Prostate-specific antigen                                                   |
| PSMF      | Pharmacovigilance system master file                                        |
| PVC       | Polyvinyl chloride                                                          |
| QA        | Quality assurance                                                           |
| QOS       | Quality Overall Summary                                                     |
| QP        | Qualified Person                                                            |
| QPPV      | Qualified person responsible for pharmacovigilance in the EU                |
| R2        | Coefficient of determination obtained from regression analysis              |
| RH        | Relative Humidity                                                           |
| RMP       | Risk management plan                                                        |
| RP        | Restricted Part (or Closed Part) of ASMF                                    |
| RRT       | Relative retention time                                                     |
| RSD       | Relative standard deviation                                                 |
| SAE       | Serious adverse event                                                       |
| SD or STD | Standard deviation                                                          |
| Thalf     | The apparent elimination half-life                                          |
| TLIN      | Start time for linear regression                                            |
| Tmax      | Time of the maximum measured analyte concentration over the sampling period |
| ULN       | Upper limit of normal                                                       |
| USP/NF    | United States Pharmacopoeia/National Formulary                              |
| UV        | Ultraviolet                                                                 |
| XRPD      | X-Ray Powder Diffraction                                                    |

<div style=\"page-break-after: always\"></div>

## 1. Background information on the procedure

## 1.1. Submission of the dossier

The applicant KRKA, d.d., Novo mesto submitted on 29 June 2020 an application for marketing authorisation to the European Medicines Agency (EMA) for Abiraterone acetate KRKA, through the centralised procedure under Article 3 (3) of Regulation (EC) No. 726/2004- 'Generic of a Centrally authorised product'.&gt;. The eligibility to the centralised procedure was agreed upon by the EMA/CHMP on 30 April 2020.&gt;

The application concerns a generic medicinal product as defined in Article 10(2)(b) of Directive 2001/83/EC and refers to a reference product, as defined in Article 10 (2)(a) of Directive 2001/83/EC, for which a marketing authorisation is or has been granted in the Union on the basis of a complete dossier in accordance with Article 8(3) of Directive 2001/83/EC.

The applicant applied for the following indication:

Abiraterone acetate KRKA is indicated with prednisone or prednisolone for:

- the treatment of newly diagnosed high risk metastatic hormone sensitive prostate cancer (mHSPC) in adult men in combination with androgen deprivation therapy (ADT)
- the treatment of metastatic castration resistant prostate cancer (mCRPC) in adult men who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicated
- the treatment of mCRPC in adult men whose disease has progressed on or after a docetaxel-based chemotherapy regimen.

## The legal basis for this application refers to:

Generic application (Article 10(1) of Directive No 2001/83/EC).

The application submitted is composed of administrative information, complete quality data and a bioequivalence study with the reference medicinal product Zytiga instead of non-clinical and clinical unless justified otherwise &gt;The chosen reference product is:

Medicinal product which is or has been authorised in accordance with Union provisions in force for not less than 8 years in the EEA:

- Product name, strength, pharmaceutical form: Zytiga 250mg tablet and Zytiga 500mg film-coated tablet
- Marketing authorisation holder: Janssen-Cilag International N.V.
- Date of authorisation: 05-09-2011
- Marketing authorisation granted by:
- -Union
- Marketing authorisation number: EU/1/11/714/001 and EU/1/11/714/002-003

Medicinal product which is or has been authorised in accordance with Union provisions in force and to which bioequivalence has been demonstrated by appropriate bioavailability studies:

- Product name, strength, pharmaceutical form: Zytiga 250mg tablet and Zytiga 500mg film-coated

<div style=\"page-break-after: always\"></div>

tablet

- Marketing authorisation holder: Janssen-Cilag International N.V.
- Date of authorisation: 05-09-2011
- Marketing authorisation granted by:
- -Union
- -Marketing authorisation numbers: EU/1/11/714/001 and EU/1/11/714/002-003
- Bioavailability study numbers: Study No. ARL/15/277 and Study No. ARL/18/135

## Information on paediatric requirements

Not applicable

## Information relating to orphan market exclusivity

## Similarity

Pursuant to Article 8 of Regulation (EC) No. 141/2000 and Article 3 of Commission Regulation (EC) No 847/2000, the applicant did not submit a critical report addressing the possible similarity with authorised orphan medicinal products because there is no authorised orphan medicinal product for a condition related to the proposed indication.

&gt;

## Scientific advice

The applicant did not seek Scientific advice from the CHMP.

## 1.2. Steps taken for the assessment of the product

The Rapporteur appointed by the CHMP was:

## Rapporteur: Nevenka Trsinar Brodt

| The application was received by the EMA on                                                              | 29 June 2020     |
|---------------------------------------------------------------------------------------------------------|------------------|
| The procedure started on                                                                                | 16 July 2020     |
| The Rapporteur's first Assessment Report was circulated to all CHMP members on                          | 5 October 2020   |
| The PRAC Rapporteur's first Assessment Report was circulated to all PRAC members on                     | 19 October 2020  |
| The CHMP agreed on the consolidated List of Questions to be sent to the applicant during the meeting on | 12 November 2020 |
| The applicant submitted the responses to the CHMP consolidated List of Questions on                     | 18 December 2020 |
| The Rapporteurs circulated the Joint Assessment Report on the                                           | 01 February 2021 |

<div style=\"page-break-after: always\"></div>

| applicant's responses to the List of Questions to all CHMP members on                                                                                                                                    |                  |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------|
| The PRAC agreed on the PRAC Assessment Overview and Advice to CHMP during the meeting on                                                                                                                 | 11 February 2021 |
| The CHMP agreed on a list of outstanding issues <in writing and/or in an oral explanation> to be sent to the applicant on                                                                                | 25 February 2021 |
| The applicant submitted the responses to the CHMP List of Outstanding Issues on                                                                                                                          | 23 March 2021    |
| The Rapporteurs circulated the Joint Assessment Report on the responses to the List of Outstanding Issues to all CHMP members on                                                                         | 07 April 2021    |
| The outstanding issues were addressed by the applicant during an oral explanation before the CHMP during the meeting on                                                                                  | N/A              |
| The CHMP, in the light of the overall data submitted and the scientific discussion within the Committee, issued a positive opinion for granting a marketing authorisation to Abiraterone acetate KRKA on | 22 April 2021    |

## 2. Scientific discussion

## 2.1. Introduction

This centralised application concerns a generic application according to article 10(1) of Directive 2001/83/EC for Abiraterone acetate Krka 500 mg film-coated tablets. The originator product is Zytiga 500 mg film-coated tablets first approved in Europe on 05 th  of September 2011 (MAA No: EU/1/11/714/001-003, Janssen-Cilag International NV).

Abiraterone acetate is an androgen biosynthesis inhibitor, converted in vivo to abiraterone. Specifically, abiraterone selectively inhibits the enzyme 17α -hydroxylase/C17,20-lyase (CYP17). This enzyme is expressed in and is required for androgen biosynthesis in testicular, adrenal and prostatic tumour tissues. CYP17 catalyses the conversion of pregnenolone and progesterone into testosterone precursors, DHEA and androstened ione, respectively, by 17α -hydroxylation and cleavage of the C17,20 bond. CYP17 inhibition also results in increased mineralocorticoid production by the adrenals.

Androgen-sensitive prostatic carcinoma responds to treatment that decreases androgen levels. Androgen deprivation therapies, such as treatment with LHRH analogues or orchiectomy, decrease androgen production in the testes but do not affect androgen production by the adrenals or in the tumour. Treatment with abiraterone decreases serum testosterone to undetectable levels (using commercial assays) when given with LHRH analogues (or orchiectomy).

Abiraterone acetate Krka is indicated in combination with prednisone or prednisolone for:

- the treatment of newly diagnosed high risk metastatic hormone sensitive prostate cancer (mHSPC) in adult men in combination with androgen deprivation therapy (ADT).
- the treatment of metastatic castration resistant prostate cancer (mCRPC) in adult men who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicated.
- the treatment of mCRPC in adult men whose disease has progressed on or after a docetaxel based chemotherapy regimen.

<div style=\"page-break-after: always\"></div>

To support this application, the applicant submitted one pivotal bioequivalence study (No.: 19-652), (fasting) and synopsis of pilot bioavailability study (No.: 19-624) as supportive study (fasting). Please refer to comments in section 3.3. Clinical aspects.

Relevant for the assessment are the Guideline on the Investigation of Bioequivalence (CPMP/EWP/QWP/1401/98) as well as the Guideline on Bioanalytical method validation (EMEA/CHMP/EWP/192217/09) and Abiraterone Product-specific Bioequivalence Guidance (EMA/CHMP/474712/2016 Rev. 1) and EMA`s Questions &amp; Answers: Positions on specific questions addressed to the Pharmacokinetics Working Party (EMEA/618604/2008) in their current version.

The Applicant did not receive CHMP Scientific Advice pertinent to the clinical investigation.

## 2.2. Quality aspects

## 2.2.1. Introduction

The finished product is presented as film-coated tablets containing 500 mg of abiraterone acetate as active substance.

Other ingredients are:

Tablet core: lactose monohydrate, hypromellose (E464), sodium laurisulfate, croscarmellose sodium (E468), silicified microcrystalline cellulose, silica colloidal anhydrous and magnesium stearate (E470b).

Film coating: macrogol, poly(vinyl alcohol), talc (E553b), titanium dioxide (E171), red iron oxide (E172) and black iron oxide (E172).

The product is available in blister (PVC/PE/PVDC//Paper/Alu): 56, 60 film-coated tablets, and blister (PVC/PE/PVDC//Paper/Alu), calendar pack: 56 film-coated tablets, as described in section 6.5 of the SmPC.

## 2.2.2. Active substance

## General information

The  chemical  name  of  abiraterone  acetate is 17-(Pyridin-3-yl)androsta-5,16-dien3β -yl acetate corresponding to the molecular formula C26H33NO2. It has a relative molecular mass of 391.55 g/mol and the following structure in Figure 1:

<div style=\"page-break-after: always\"></div>

Figure 1: abiraterone acetate structure

<!-- image -->

The chemical structure of abiraterone acetate was elucidated by a combination of elemental analysis, UV spectroscopy, FT-IR spectroscopy, nuclear magnetic resonance ( 1 H-NMR  and 13 C-NMR),  mass spectrometry, thermal analysis (DSC) and thermo gravimetric analysis (TGA).

The active substance is a white to off-white powder practically insoluble in water and is insoluble in water and in aqueous buffers with pH 1.2-8.0.

Abiraterone  acetate  exhibits  polymorphism.  The  polymorphic  form  of  abiraterone  acetate  can  be distinguished by XPRD.

Abiraterone acetate is a single enantiomer containing 8 stereochemical elements: 6 chiral centres and 2 centres of geometrical isomerism. Abiraterone acetate is produced as a single enantiomer. The optical purity is adequately controlled.

## Manufacture, characterisation and process controls

Detailed information on the manufacturing of the active substance has been provided in the restricted part of the ASMF and it was considered satisfactory.

The manufacturing process consists of several synthetic steps.

Only one site is involved in the manufacture and micronisation of the active substance. The starting materials  are  acceptable  and  are  controlled  by  suitable  specifications.  During  the  synthesis,  several intermediates  are  isolated  and  are  sufficiently  controlled.  In  addition,  acceptable  specifications  for reagents, solvents and other materials used in the synthesis have been provided. Critical steps of the process were identified and are controlled by justified and appropriate in-process controls.

The stability data for reprocessed batch has been included in stability section.

The characterisation of the active substance and its impurities is in accordance with the EU guideline on chemistry of new active substances. Potential and actual impurities were well discussed with regards to their  origin  and  characterised.  The  information  presented  regarding  potential  impurities/degradation products  controlled  in  the  active  substance  is  sufficient.  Overall  the  defined  control  strategy  is satisfactory.

Abiraterone acetate is packed in a suitable container. The primary packing material complies with the EC directive 2002/72/EC and EC 10/2011 as amended.

## Specification

The active substance specification includes tests for appearance, identification (IR, HPLC), water content (Ph. Eur, in-house), specific optical rotation (Ph. Eur), sulphated ash (Ph. Eur.), content of abiraterone acetate (Ph. Eur, in-house), impurities (HPLC, in-house), residual solvents (GC), particle size (Ph. Eur, in-house) and microbiological quality (Ph. Eur).

<div style=\"page-break-after: always\"></div>

The specification limits for impurities/degradation products and residual solvents are in accordance with the requirements of ICH guidelines Q3A and Q3C. All solvents used throughout the entire synthetic process,  including  those  employed  prior  to  the  starting  material,  are  routinely  controlled  in  the specification and specified at levels below the ICH Q3C thresholds.

The analytical methods used have been adequately described and non-compendial methods appropriately validated in accordance with the ICH guidelines. The finished product manufacturer has adopted the analytical methods for content of abiraterone acetate and for related substances. For the test on residual solvents the same analytical procedure is used by the finished product manufacturer as followed  by  active  substance  manufacturer.  All  other  analytical  methods  are  Ph.  Eur.  Methods. Satisfactory information regarding the reference standards used has been presented.

Batch  analysis  data  from  several  production  scale  batches  generated  by  both  active  substance  and finished product manufacturers was provided, demonstrating compliance with the proposed specifications. The batch data provided is considered to be sufficient. Consistency and uniformity of the active substance quality have been demonstrated.

## Stability

Stability data from several commercial scale batches and micronisation validation batch stored for up to 60 months under long term conditions (25±2°C / 65±5% RH) and for up to 6 months under accelerated conditions  (40±2°C  /  75±5%  RH)  according  to  the  ICH  guidelines  were  provided.  The  batches  of medicinal  product  are  identical  to  those  proposed  for  marketing  and  were  packed  in  the  primary packaging proposed for marketing.

All tested parameters were within the specifications.

Photostability studies  were  conducted  in  line  with  ICH  Q1B  requirements.  Additionally,  the  force degradation study has been demonstrated to be stability indicating.

The  stability  results  indicate  that  the  active  substance  manufactured  by  the  proposed  suppliers  is sufficiently stable. The stability results justify the proposed retest period when stored in the proposed container with specified storage conditions.

## 2.2.3. Finished medicinal product

## Description of the product and Pharmaceutical development

The finished product is a film-coated tablet for oral administration containing 500 mg of abiraterone acetate. The film-coated tablets are presented as grey violet to violet oval biconvex film-coated tablets. Approximate tablet dimensions: tablets are 20 mm long by 10 mm wide.

The qualitative composition is listed below:

Active substance: Abiraterone acetate.

Tablet core: lactose monohydrate, hypromellose (E464), sodium laurisulfate, croscarmellose sodium (E468), silicified microcrystalline cellulose, silica colloidal anhydrous, magnesium stearate (E470b) and purified water.

<div style=\"page-break-after: always\"></div>

Film coating: macrogol, poly(vinyl alcohol), talc (E553b), titanium dioxide (E171), red iron oxide (E172), black iron oxide (E172) and purified water. Abiraterone Krka 500 film-coated tablets was developed with the objective of designing a bioequivalent, effective and safe generic equivalent to the originator medicinal product Zytiga 500 mg film-coated tablets of specified quality, manufactured by simple and reproducible technological process to consistently deliver the intended performance of the medicinal product - easily manufactured, stable formulation in the proposed packaging. Abiraterone acetate is practically insoluble in water. Abiraterone acetate is a BCS class IV compound with low solubility and low permeability across physiological pH range. All excipients are well known pharmaceutical ingredients and their quality is compliant with Ph. Eur. standards with exception of some of them which are referred to USP/NF or in house specification. There are no novel excipients used in the finished product formulation. The list of excipients is included in section 6.1 of the SmPC. These are: lactose monohydrate; hypromellose; sodium laurylsulfate; croscarmellose sodium; cellulose, silicified microcrystalline (type 90) comprises of microcrystalline cellulose and colloidal anhydrous silica; silica colloidal anhydrous ; magnesium stearate. The coating material used for the 500 mg strength contains also polyvinyl alcohol, titanium dioxide (E171), macrogol 3350, talc, iron oxide black (E172) and iron oxide red (E172). The selected ingredients for film coating have well known chemical, physical and microbial characteristics and comply with relevant Ph. Eur. Monographs and EU 231/2012 Regulation. Silicified microcrystalline cellulose (type 90) (SMCC 90) is considered as co-processed excipient. A manufacturing process of SMCC 90 has been described in section 3.2.P.3.3 in the manufacturing process flowchart and detailed description of the manufacturing process including process settings and in process controls. It is composed of microcrystalline cellulose co-processed with colloidal silicon dioxide. Because water is used during manufacturing process of silicified microcrystalline cellulose the applicant is strongly encouraged to change the quality to purified water, Ph. Eur., by a variation application postapproval. The requirements (Guideline on the quality of water for pharmaceutical use (EMA/CHMP/CVMP/QWP/496873/2018)) for water used during the manufacture of active substances (point 5.2) could not be extrapolated to the excipients. Water, used during manufacture of medicinal products but not present in the final formulation, is recommended to be purified. See recommendation in section 2.2.6. A compatibility study was performed to examine the interactions between the active substance and the proposed excipients. This was performed through the ICH stability studies under accelerated and longterm conditions. No significant increase in abiraterone acetate related substances was found in the compatibility study. From the results, it could be concluded that the active substance is compatible with the excipients used in Abiraterone 500 mg film-coated tablets. In order to assess pharmaceutical equivalence, Abiraterone Krka 500 mg film-coated tablets was compared to Zytiga 500 mg film-coated tablets versus their quality characteristics - impurities and their in vitro performance - dissolution profiles. In the beginning of the development phase of Abiraterone 500 mg film-coated tablets and according to the 'Guideline on the investigation of bioequivalence' (CPMP/EWP/QWP/1401 98 Rev.1/Corr**), solubility study of abiraterone acetate in physiological pH range from acidic to neutral pH was performed. Solubility characteristics of abiraterone acetate were determined and selected dissolution media justified.

<div style=\"page-break-after: always\"></div>

Development of the dissolution method was guided by the recommendations of the relevant chapters of the European Pharmacopoeia 'Guidance on dissolution testing' and relevant sections of guideline CPMP/EWP/QWP/1401/98 Rev.1/Corr**. In compliance with the above guidelines, the basic criteria, were discriminatory power of the method, reflection of in vivo complete release of active substance within the specified time and appropriate robustness for routine QC testing. The dissolution testing was conducted using Ph. Eur. compliant equipment.

Formulation development was initiated with an evaluation of the characteristics of the reference after scale-up experiment,  and high-shear granulation was selected as the final manufacturing procedure for present formulation.

which governed the choice of the dissolution method (apparatus, medium, volume and stirring speed), conditions, fulfilment of sink conditions, The selected dissolution method for Abiraterone 500 mg film-coated tablets has appropriate discriminatory power. The bioequivalence study was conducted in order to compare the bioavailability of Abiraterone Krka 500 mg film-coated tablets and Zytiga 500 mg film-coated tablets. The study was a single-center, randomized, single-dose cross-over study conducted under fasting conditions with a 7 days washout period between the doses. The formulation used in the bioequivalence study were manufactured by the same manufacturer, same manufacturing process and same type of equipment. The assayed content of test batches does not differ more than 5% from that of the reference batches, there is also no observed difference in the impurity profile. The production batch size is the same as the size of batches in the bioequivalence study. Based on the results, bioequivalence is concluded between test and reference formulation. The formulation used during clinical studies is the same as that intended for marketing. product, Zytiga film-coated tablets. Fluid bed granulating technique was selected for manufacturing the Zytiga 500 mg formulation as per EPAR. However, fluid bed granulating technique was later abandoned

The  primary  packaging  is  blister  (PVC/PE/PVDC//Paper/Alu):  56,  60  film-coated  tablets,  and  blister (PVC/PE/PVDC//Paper/Alu), calendar pack: 56 film-coated tablets as stated in the SmPC. The material complies  with  Ph.Eur.  and  EC  requirements.  The  choice  of  the  container  closure  system  has  been validated by stability data and is adequate for the intended use of the product.

## Manufacture of the product and process controls

There is only one manufacturer of the finished product. The manufacturing process consists of four main steps:  dispensing;  manufacturing  of  granulate;  manufacturing  of  compression  mixture;  tabletting process and film-coating process. The process is considered to be a standard manufacturing process.

Major steps of the manufacturing process have been validated by a number of studies. It has been demonstrated that the manufacturing process is capable of producing the finished product of intended quality in a reproducible manner. The in-process controls are adequate for this type of manufacturing process and pharmaceutical form.

## Product specification

The finished product release and shelf-life specifications include appropriate tests for this kind of dosage form: appearance (visual), uniformity of dosage unit - mass variation (Ph. Eur), identification of abiraterone acetate (HPLC), content of abiraterone acetate (HPLC), dissolution, impurities (HPLC) and microbial quality (Ph. Eur).

<div style=\"page-break-after: always\"></div>

The proposed specification is considered acceptable.

The potential presence of class 1 (As, Cd, Hg and Pb) and Class 2A (Co Ni, V) elemental impurities in the finished product has been assessed using a risk-based approach in line with the ICH Q3D Guideline for Elemental Impurities. Furthermore Se, Sb, Ba, Mo, Cu, Sn and Cr were also included in the risk assessment, because of their naturally occurring as contaminants in mined substances (coating mixture (talc and titanium oxide), iron oxide). Batch analysis data using a validated ICP-MS method was provided, demonstrating that each relevant elemental impurity was not detected above 30% of the respective PDE. Based on the risk assessment and the presented batch data it can be concluded that it is not necessary to include any elemental impurity controls. The information on the control of elemental impurities is satisfactory.

The applicant was requested to provide a risk evaluation concerning the presence of nitrosamine impurities in the product in question; this was raised as a MO during the procedure. In response to this MO, a risk assessment concerning the presence of nitrosamine impurities was performed for the finished product based on the combined recommendations from health authorities. A statement that there is no risk of N-nitrosamine contamination has been provided and it was concluded that there is no risk related to the presence of nitrosamine impurities in the product. Therefore, no changes to the control strategy for Abiraterone Krka are necessary to mitigate potential contamination by nitrosamines. The nitrosamine impurities risk assessment of the finished product included evaluating contributions from abiraterone acetate active substance, excipients, finished product manufacturing facilities, and packaging components.

The analytical methods used have been adequately described and appropriately validated in accordance with the ICH guidelines. Satisfactory information regarding the reference standards used for assay and impurities testing has been presented.

The finished product is released onto the market based on the above release specifications, through traditional final product release testing.

Batch analysis results are provided for three commercial scale batches confirming the consistency of the manufacturing process and its ability to manufacture to the intended product specification.

## Stability of the product

Stability data from several commercial batches of finished product stored for up to 12 months under long term conditions (25°C / 60% RH) and up to 6 months under accelerated conditions (40°C / 75% RH) according to the ICH guidelines were provided. For bulk product, adequate stability results at long term condition  25°C/60%  RH  supporting  proposed  bulk  holding  were  also  presented.  The  batches  of Abiraterone Krka 500 mg film-coated tablets are identical to those proposed for marketing and were packed in the primary packaging proposed for marketing.

The analytical procedures used are stability indicating. A trend of increasing specified and total impurities was  observed  at  accelerated  and  long-term  conditions.  Results  for  unspecified  impurities  are  below reporting level ( ≤ 0.05%). All results are within the proposed limits.

Photostability study was conducted according to ICH Q1B, Option 2. Samples were tested for appearance, content of abiraterone acetate, dissolution and impurities. Test was performed on tablets stored outside the immediate packaging and exposed to light in a single layer on open Petri dish at controlled conditions 25°C/40%RH.  Film-coated  tablets  outside  the  original  packaging  and  exposed  to  light  showed  no sensitivity of the product to the light and no trends were observed on any of the tested parameters. Based on the results, it can be concluded that the finished product is found to be stable to light exposure.

<div style=\"page-break-after: always\"></div>

According to the compliance of the results with the specification limits at accelerated conditions and according to photostability study results no special storage conditions is proposed. Therefore, based on available stability data, the proposed shelf-life of 24 months with no special storage conditions as stated in the SmPC (section 6.3) are acceptable.

## Adventitious agents

Lactose monohydrate is the only material of animal origin used in the production of Abiraterone filmcoated tablets. It is confirmed that the lactose is produced from milk from healthy animals in the same condition as those used to collect milk for human consumption and that the lactose has been prepared without the use of ruminant material other than calf rennet according to the Note for Guidance on Minimising the Risk of Transmitting Animal Spongiform Encephalopathy Agents Via Human and veterinary medicinal products. Valid TSE CEP is provided.

Magnesium stearate is of vegetable origin. Statement from manufacturer confirming origin of magnesium stearate is presented.

## 2.2.4. Discussion on chemical, and pharmaceutical aspects

Information on development, manufacture and control of the active substance and finished product has been presented in a satisfactory manner.

The MO raised during the procedure regarding the potential presence of nitrosamines in the finished product was resolved by performing and presenting a satisfactory risk assessment as per the relevant published guidance. The results of tests carried out indicate consistency and uniformity of important product quality characteristics, and these in turn lead to the conclusion that the product should have a satisfactory and uniform performance in clinical use.

At the time of the CHMP opinion, there was one minor unresolved quality issue having no impact on the Benefit/Risk ratio of the product, which pertain to the quality standard of the water used in the manufacturing process of silicified microcrystalline cellulose. This point is put forward and agreed as recommendation for future quality development (see section 2.2.6).

## 2.2.5. Conclusions on the chemical, pharmaceutical and biological aspects

The quality of this product is considered to be acceptable when used in accordance with the conditions defined in the SmPC. Physicochemical and biological aspects relevant to the uniform clinical performance of the product have been investigated and are controlled in a satisfactory way. Lactose monohydrate is the only material of animal origin used in the manufacture of Abiraterone Acetate filmcoated tablets. Data has been presented to give reassurance on TSE safety.

## 2.2.6. Recommendation for future quality development

In the context of the obligation of the MAHs to take due account of technical and scientific progress, the CHMP recommends the following points for investigation:

- To submit a variation post-approval in 2 years' time frame after approval to change the quality of water used during manufacturing process of silicified microcrystalline cellulose to purified water. The requirements (Guideline on the quality of water for pharmaceutical use

(EMA/CHMP/CVMP/QWP/496873/2018)) for water used during the manufacture of active substances

<div style=\"page-break-after: always\"></div>

(point 5.2) could not be extrapolated to the excipients. Water, used during manufacture of medicinal products but not present in the final formulation, is recommended to be purified.

## 2.3. Non-clinical aspects

## 2.3.1. Introduction

Pharmacodynamic, pharmacokinetic and toxicological properties of abiraterone are well known. As abiraterone is a widely used, well-known active substance, additional studies and further studies are not required. Overview based on literature review is appropriate.

The impurity profiles of Abiraterone acetate Krka 500 mg tablets were compared to that of the reference product Zytiga 500 mg tablets. Both test and reference products exhibit similar impurity profiles. The specifications set for all impurities are in accordance with the currently valid USP monograph for abiraterone acetate tablets and the ICH Q3B guideline and thus acceptable.

The excipients used in drug formulation are conventional, well known and broadly used in other medicinal products.

The non-clinical aspects of the SmPC are in line with the SmPC of the reference product (Zytiga SmPC, 2020).

Therefore, the CHMP agreed that no further non-clinical studies are required.

## 2.3.2. Ecotoxicity/environmental risk assessment

No Environmental Risk Assessment studies were submitted. This was justified by the applicant as the introduction of Abiraterone KRKA is considered unlikely to result in any significant increase in the combined sales volumes for all abiraterone acetate containing products and the exposure of the environment to the active substance. Thus, the ERA is expected to be similar.

SmPC of the generic product, section 5.3 contains the same information as the innovator: 'The active substance, abiraterone, shows an environmental risk for the aquatic environment, especially to fish.'

## 2.3.3. Discussion on non-clinical aspects

In line with the requirements for generic products, no new non-clinical data was submitted. The nonclinical data, based on literature review of published studies, are acceptable since abiraterone is wellknown active substance clinically used in humans for more than 10 years.

The presented Non-clinical Overview is considered sufficient for this type of MAA.

The impurity profile has been discussed and was considered acceptable.

The excipients used in drug formulation are conventional, well known and broadly used in other medicinal products.

The Applicant's justification for omission of environmental risk assessment studies is considered acceptable.

<div style=\"page-break-after: always\"></div>

The non-clinical data is reflected in the appropriate sections of the SmPC (Sections 4.6 and 5.3). The non-clinical aspects of the SmPC are in line with the SmPC of the reference product (Zytiga SmPC, 2020).

## 2.3.4. Conclusion on the non-clinical aspects

A summary of the literature with regard to non-clinical data of Abiraterone acetate KRKA and justifications that the active substance does not differ significantly in properties with regards to safety and efficacy of the reference product was accepted by the CHMP. This is in accordance with the relevant guideline and additional non clinical studies were not considered necessary.

## 2.4. Clinical aspects

## 2.4.1. Introduction

This  centralised  application  concerns  a  generic  application  according  to  article  10(1)  of  Directive 2001/83/EC for Abiraterone acetate Krka 500 mg film-coated tablets with abiraterone acetate as active substance.  Essential  similarity  is  claimed  to  Zytiga  containing  abiraterone  acetate,  Janssen-Cilag International  N.V.,  Belgium  approved  via  centralised  procedure  since  5th  of  September  2011 (EU/1/11/714/002-003).

A clinical overview has been provided, which is based on up-to-date and adequate scientific literature.

To support this application, the applicant submitted one pivotal bioequivalence study (No.: 19-652) in fasting condition. In addition, the applicant submitted the synopsis of the pilot bioavailability study (No.: 19-624) as supportive study (fasting).

The bioequivalence is based on the results of the pivotal study (No.: 19-652). The pilot study (No.: 19624) is not discussed in this report.

## GCP

The Clinical trials were performed in accordance with GCP as claimed by the applicant

The applicant has provided a statement to the effect that clinical trials conducted outside the community were carried out in accordance with the ethical standards of Directive 2001/20/EC.

## Clinical studies

To support the application, the applicant has submitted one bioequivalence study (No: 19-652). In addition, the applicant presented synopsis of pilot bioavailability study (No: 19-624) as supportive information.

Table 1 Tabular overview of clinical studies

| Type of Stud y   | Study Identifie r   | Locatio n of Study Report   | Objective( s) of the Study   | Study Design and Type of Control   | Test Product(s); Dosage Regimen;   | Numbe r of Subject s   | Healthy Subjects or Diagnosi s of Patients   | Duration of Treatme nt   | Study Status; Type of Report   |
|------------------|---------------------|-----------------------------|------------------------------|------------------------------------|------------------------------------|------------------------|----------------------------------------------|--------------------------|--------------------------------|

<div style=\"page-break-after: always\"></div>

|    |        |                  |                                                                                                  |                                           | Route of Administrati on                                                                                                                                                                                                             |     |                  |             |                 |
|----|--------|------------------|--------------------------------------------------------------------------------------------------|-------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|------------------|-------------|-----------------|
| BE | 19-652 | Section 5.3.1.2. | To compare the rate and extent of absorption of abiraterone from the test and reference products | Crossover, semi-replicat e, fasting state | Test product: Abiraterone 500 mg film-coated tablets (KRKA, d.d., Novo mesto) Reference product: Zytiga® (abiraterone acetate) 500 mg film-coated tablets (Janssen-Cilag International N.V.) One film-coated tablet per period; Oral | 102 | Healthy subjects | Single dose | Complet e; Full |

## 2.4.2. Pharmacokinetics

Study No.19-652, A Single-Dose, Semi-Replicate, Bioequivalence Study of Two Formulations of Abiraterone Acetate 500 mg Film-Coated Tablets under Fasting Conditions

## Methods

## Study design

Study No.19-652  was an open-label, single-dose, randomized, three-period, two-treatment, twosequence, cross-over, semi-replicate study, designed to evaluate the bioequivalence of abiraterone in healthy, non-smoking, male subjects under fasted conditions with a washout period of 7 days between drug administrations. In each period, subjects were administered a single, oral dose of either the test or reference product, in accordance with the randomization scheme, after an overnight fast of at least 10 hours.

The primary objective of this study was to evaluate the bioequivalence between Abiraterone 500 mg film-coated tablets (MAH: KRKA, d.d., Novo mesto, SLOVENIA, EU) and Zytiga ® (abiraterone acetate) 500 mg film-coated tablets (MAH: Janssen-Cilag International NV, Belgium, EU) after a single dose in healthy male subjects under fasted conditions.

The secondary objective of this study was to evaluate the safety and tolerability of the study treatments.

## Summary of study information

| Clinical Study Dates:   | December 06, 2019 (ICF signature) - March 02, 2020 (Last Subject Assessment)   |
|-------------------------|--------------------------------------------------------------------------------|

<div style=\"page-break-after: always\"></div>

|                                    | Treatment Dosing Dates: Period-I: December 07, 2019 Period-II: December 14, 2019 Period-III: December 21, 2019 Last Pharmacokinetic (PK) Blood Sample: December 23, 2019   |
|------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Date of the Clinical Study Report: | May 11, 2020                                                                                                                                                               |
| Bioanalytical Study Dates:         | 02 January 2020 - 17 January 2020                                                                                                                                          |

Both the clinical study site and the bioanalytical site have been inspected by an EU competent authority.

In order to assess the within-subject variability for Cmax of the reference product and to justify widening of  a  confidence  interval  for  Cmax,  this  study  included  semi-replicate  administration  of  the  test  and reference products in 3-period cross-over design, where treatments are given in the order sequences TRR, RTT. The within subject variability were estimated for both test and reference products. The TRR, RTT replicate design is considered appropriate to assess the within-subject variability for Cmax of the reference product as more than 12 subjects were allocated in each arm. This complies with the EMA `s question number 19 of Questions &amp; Answers Document (EMA/618604/2008 Rev. 13).

The study was conducted in three periods and in each period the subjects received either test or reference products randomly as per the predetermined computer-generated randomization scheme (procedure PLAN in SAS® version 9.4) and under open-label conditions. The dosing (treatment) of test and reference product were given in two sequences (TRR, RTT). Subjects who were assigned sequence TRR received test product (T) in period-1 and reference product (R) in period-2 and 3. Subjects who were assigned sequence RTT received R product in Period-1 and T product in period-2 and 3. Dosing occurred following an overnight fast of at least 10 hours. There was a 7-day washout period between dosing times for the two treatment periods. The pre-dose concentrations of abiraterone, which was less than 5% of their Cmax were observed for 3 subjects before the period-2 or period-3 drug administration at time 0.00h.

In each study period, blood samples were collected within 60 minutes prior to dose administration (0 hour) and at intervals over 48.00 hours after administration of dose, totalling 22 samples in each period. Considering the expected time to peak concentration (approximately 2 hours) and the elimination halflife (approximately 15 hours), the sampling schedule and the sampling time period of 48 hours seems long enough to estimate PK parameters (Cmax, AUC0-t and Tmax).

The quantification of abiraterone in human plasma was performed using liquid chromatographic tandem mass spectrometric detection (LC-MS/MS) method.

## Test and reference products

| Product Characteristics   | Test product                            | Reference Product                   |
|---------------------------|-----------------------------------------|-------------------------------------|
| Name                      | Abiraterone 500 mg film- coated tablets | Zytiga ® 500 mg film-coated tablets |
| Strength                  | 500 mg                                  | 500 mg                              |

<div style=\"page-break-after: always\"></div>

| Dosage form                                                 | Film-coated tablets                                 | Film-coated tablets                                                                                    |
|-------------------------------------------------------------|-----------------------------------------------------|--------------------------------------------------------------------------------------------------------|
| Batch number                                                | RA0258                                              | IGZSB00                                                                                                |
| Expiry date (Retest date)                                   | (17/01/2020)                                        | 06/2020                                                                                                |
| Location of Certificate of Analysis                         | Appendix 16.1.6                                     | Appendix 16.1.6                                                                                        |
| Member State where the reference product is purchased from: |                                                     | Germany, EU                                                                                            |
| This product was used in the following trials:              | Sponsor Project N° 19- 652 CRO Project N° 2020-4801 | Sponsor Project N° 19-624 CRO Project N° KRS-P6-263 Sponsor Project N° 19-652 CRO Project N° 2020-4801 |

Zytiga 500 mg film-coated tablets is an immediate release tablet formulation containing abiraterone, which was approved in Europa on 5th of September 2011, through a centralised marketing authorization procedure under Article 8.3 of Directive 2001/83/EC. Therefore, the choice of the reference medicinal product is acceptable. The member state where the reference product was purchased from is Germany, EU.

Satisfactory certificates of analysis of the test and reference products bio-batch are presented. The difference in the assay between the test and reference product is less than 5%, which is acceptable. This difference was not taken into account in the pharmacokinetic or statistical analysis.

## Population(s) studied

A total of 102 non-smoker, healthy, adult, male volunteers 18 to 65 years of age, having a Body Mass Index (BMI) between ≥18.5 and ≤30.0 kg/m2 and weight ≥50 kg with normal clinical and laboratory results, were enrolled in the study. The population chosen was appropriate and in line with the Guideline on the investigation of Bioequivalence/CMP/EWP/QWP/1404/98 Rev.1/Corr** . All the subjects were dosed as per the randomization. Male subjects participated in the study met the inclusion criteria and did not fulfil any of the exclusion criteria described in the study protocol.

Out of the 102 subjects , 98 subjects completed all 3 periods of the study ,101 subjects completed at least two periods and were included in the Pharmacokinetic and Statistical analysis .

The safety assessment includes information for all 102 subjects who received at least one administration of any study treatment.

Drop-outs and missing samples:

Two subjects discontinued after completing period-1 and 2, due to AEs (libido decreased and scrotal discomfort; pyrexia). Plasma samples of both subjects were analysed as per protocol requirement. And data from both subjects were included in the PK and Statistical analyses.

One subject who discontinued after period-1 of drug administration due to personal reasons. was excluded from the PK and statistical analyses.

A fourth subject discontinued after completing period-1 due to personal reason but returned in period3 to complete the study. The subject completed two periods (period-1 with test product and period-3 with reference product), hence the subject was included in the PK and Statistical analyses.

One subject completed the study with missing Period-3 sample of reference product at 48 hours post dose.

Protocol Deviations

<div style=\"page-break-after: always\"></div>

| Protocol Deviation Nunber   | Protocol Section                      | Details                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
|-----------------------------|---------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 2020-4801- P01              | 10.12PharmacokineticSample Collection | could not beverified.The sample was collected,processed in accordance with the protocol, and the scheduled time of collection was used in the PK analysis. Therefore, this deviation had no significant impact on the integrity of the study results. The actual time of collection ofthe PK sample from period 3,48hours postdose, could not be verified. The sample was collected, processed in accordance with the protocol, and the scheduled time of collection was used in the PK analysis. Therefore, this deviation had no significant impact on the integrity of the study results. The actual time of collection of the PK sample from period 1, 3.5 hours postdose, could notbe verified.The sample was collected,processedin accordance with the protocol, and the scheduled time of collection was used in the PK analysis. Therefore,thisdeviationhadnosignificantimpact on theintegrity ofthestudy results. |

| Protocol Deviation Number   | Protocol Section                        | Details                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
|-----------------------------|-----------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 2020-4801- P01              | 10.12 Pharmacokinetic Sample Collection | The actual time of collection of the PK sample from period 2, 36 hours postdose, could not be verified. The sample was collected, processed in accordance with the protocol, and the scheduled time of collection was used in the PK analysis. Therefore, this deviation had no significant impact on the integrity ofthe study results.                                                                                                                                                                                                                                                                                                                                                                           |
| 2020-4801- P01              | 10.12PharmacokineticSample Collection   | No PK sample was collected during period 3 at 48 hours postdose because the subject did not retum to the clinic.The corresponding abiraterone concentration value was set to missing for the purposes of the PK analysis and the impact on the integrity of the study results was not significant.                                                                                                                                                                                                                                                                                                                                                                                                                 |
| 2020-4801- P01              | 10.12 Pharmacokinetic Sample Collection | ThePKsample scheduledfor collection at 48hourspostdose inperiod3was collected 186minutes prior to the scheduled time.A PK scientist was not consulted to assess the continuedparticipation of the subject in the study.The actual time of collectionwas usedinthePK analysis and thisdeviation had no significant impact on theintegrity ofthestudyresults.                                                                                                                                                                                                                                                                                                                                                        |
| 2020-4801- P02              | 10.9 Vital Signs Measurements           | Systolic and diastolicbloodpressure,butnotpulse rate,was documented in period 1, 4.5 hours postdose. A pulse rate within normal limits was obtained as part of an electrocardiogram recording 59 minutes prior to the time of the measurement of vital signs.The blood pressure measurements werewithin normal limits.This deviation had no significant impact on the safety of the subject or on the integrity ofthe studyresults. Vital signs measurements were obtained during period3,8hours postdose,at 5 minutes before the earliest allowable time. The measurements were within normal limits. This deviation had no significant impact on the safety of the subject or on the integrityofthestudyresults. |
| PK, pharmacokinetic.        | PK, pharmacokinetic.                    | PK, pharmacokinetic.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |

## Analytical methods

Pre-study and in-study validations were performed according to the requirements of the EMA Guideline on bioanalytical method validation (EMEA/CHMP/EWP/192217/09).

<div style=\"page-break-after: always\"></div>

Plasma concentrations of abiraterone in subject samples were measured utilizing Analyst® Software Version 1.6.3, according to an achiral, liquid chromatographic tandem mass spectrometric detection (LC-MS/MS) method. The analytical method used for the study is the same as the validated method. Calibration curve standards and quality control samples met the acceptance criteria for all the runs used for the final data, demonstrating satisfactory performance of the method during the analysis of study subject samples. 119 subject samples were repeated in accordance with. due to unacceptable internal standard response, injection error, extraction error, poor chromatography, above the Upper Limit of Quantitation and to confirm presence of peak in pre-dose. The reasons for reanalysis of samples in each of the sample analysis are considered justified. 385 study samples were re-assayed in accordance with SOP. ISR was performed with more than 5 % of the samples as requested by the guideline for total number samples exceeding 1000 samples. The ISR assay complied with the acceptance criteria as all samples (100%) were within the acceptance criteria (±20%) indicating that the analysis is robust. Deviations

Two deviation occurred during analysis of the study samples.

## Pharmacokinetic variables

The PK parameters Cmax, AUCt, AUCinf, Tmax, Kel, and Thalf estimated for abiraterone were computed using a noncompartmental approach in Phoenix™ WinNonlin®, Version 8.1. Primary pharmacokinetic parameters: were Cmax, AUC0-t and AUC0-∞ Secondary pharmacokinetic parameters wereTmax, Kel, and Thalf The selected primary pharmacokinetic variables are appropriate for a single dose bioequivalence study and in line with the Guideline on the Investigation of Bioequivalence (CPMP/EWP/QWP/1401/98 Rev.1) Pharmacokinetic software and method for PK parameters estimation are considered acceptable.

Actual time of blood collection was considered for pharmacokinetic calculations.

## Statistical methods

Descriptive statistics for the PK parameters of abiraterone were calculated and included number of observations, arithmetic mean, standard deviation (SD), geometric mean (where applicable), coefficient of variation (CV), median, minimum, and maximum. Statistical analysis was performed on log-transformed pharmacokinetic parameters AUCt, AUCinf, and Cmax of abiraterone using the SAS® package (Version 9.4, PROC MIXED of SAS). Analysis of variance (ANOVA) was performed on log-transformed pharmacokinetic parameters AUCt, AUCinf, and Cmax of abiraterone using PROC MIXED procedure in SAS®, Software, Version 9.4 or higher. The significance of the sequence, period, and treatment effects (all fixed) was tested.

.

<div style=\"page-break-after: always\"></div>

Using the same statistical model, the least-squares-means (LSMs), the differences between the treatments LSMs, and the corresponding standard errors of these differences were estimated for logtransformed AUCt, AUCinf, and Cmax parameters. Based on these statistics, the ratios of the geometric means for treatments and the corresponding 90% confidence intervals (CIs) were calculated.

To assess the within-subject variability of this drug, this study employed a replicate administration of the reference product. The intra-subject-within-reference variability, SWR, was estimated using the data from subjects who completed 2 administrations of the reference product. The comparison of Cmax (R1 versus R2) was carried out using PROC GLM procedure. The statistical model included sequence, subject-within-sequence, and period as factors. The residual variance corresponds to intra-subjectwithin-reference variability.

Standard bioequivalence criteria were proposed for AUC0-t and AUCinf while a wider bioequivalence interval was proposed for Cmax if the reference product has a highly variable intra-subject variability (&gt;30%) as indicated in the EMA Guideline on the Investigation of Bioequivalence .

Although the widening of the acceptance criteria for Cmax has been adequately justified, the 90%CI for Cmax of abiraterone lie within the acceptance range of 80 - 125% and therefore a justification for widening of the acceptance criteria for Cmax is of no more relevance.

Protocol deviations/violations were not reported with regards the statistical analysis of the study.

## Results

The pharmacokinetic parameters of abiraterone  for  Test  Product  (T)  and  Reference  Product  (R)  are summarized in the following tables:

Table 2 : Pharmacokinetic parameters for abiraterone (non-transformed values) (Study No. 19-652)

Table14-2 DescriptiveStatisticsforPlasma AbirateronePharmacokineticParaimeters

| Parameter   | Trt   | GeoMean   | ArithMean   | SD      | CV%   | Median   | Minimum   | Maximum   | N   |
|-------------|-------|-----------|-------------|---------|-------|----------|-----------|-----------|-----|
| AUC,        | A     | 303.605   | 356.722     | 209.707 | 58.79 | 315.976  | 60.575    | 1038.567  | 149 |
| (hr*ng/mL)  | B     | 316.680   | 378.234     | 229.061 | 60.56 | 318.335  | 79.085    | 1120.155  | 151 |
| AUCinf      | A     | 329.882   | 383.914     | 219.458 | 57.16 | 337.266  | 64.458    | 1077.263  | 146 |
| (hr*ng/mL)  | B     | 344.688   | 407.283     | 238.656 | 58.60 | 346.437  | 92.026    | 1172.270  | 149 |
| AUC/AUCimf  | A     | 92.74     | 92.88       | 4.67    | 5.03  | 93.91    | 58.60     | 99.38     | 146 |
| (%)         | B     | 91.99     | 92.30       | 6.86    | 7.44  | 94.56    | 53.05     | 98.56     | 149 |
| Cmax        | A     | 56.932    | 69.089      | 44.785  | 64.82 | 56.000   | 9.420     | 282.000   | 149 |
| (ng/mL)     | B     | 60.409    | 72.542      | 43.408  | 59.84 | 64.100   | 14.400    | 216.000   | 151 |
| Tmax        | A     | 1.71      | 1.98        | 1.18    | 59.74 | 1.67     | 0.67      | 7.00      | 149 |
| (hr)        | B     | 1.86      | 2.13        | 1.23    | 57.49 | 1.67     | 0.67      | 9.00      | 151 |
| Thalf       | A     | 15.92     | 16.51       | 4.86    | 29.45 | 15.71    | 7.43      | 48.02     | 146 |
| (hr)        | B     | 16.08     | 17.11       | 7.10    | 41.48 | 14.74    | 8.48      | 50.76     | 149 |
| Ke          | A     | 0.0435    | 0.0450      | 0.0118  | 26.21 | 0.0441   | 0.0144    | 0.0932    | 146 |
| (1/hr)      | B     | 0.0431    | 0.0453      | 0.0131  | 29.03 | 0.0470   | 0.0137    | 0.0818    | 149 |
| TLIN        | A     | 15.35     | 16.17       | 5.28    | 32.62 | 16.00    | 7.00      | 24.03     | 146 |
| (hr)        | B     | 16.00     | 16.84       | 5.32    | 31.57 | 16.00    | 6.00      | 24.13     | 149 |
| R²          | A     | 0.9749    | 0.9755      | 0.0344  | 3.53  | 0.9892   | 0.8269    | 1.0000    | 146 |
|             | B     | 0.9739    | 0.9746      | 0.0377  | 3.87  | 0.9891   | 0.8013    | 1.0000    | 149 |
| LQCT        | A     | 47.69     | 47.69       | 0.87    | 1.82  | 47.70    | 44.90     | 49.72     | 149 |
| (hr)        | B     | 47.64     | 47.66       | 1.29    | 2.71  | 47.75    | 35.00     | 49.12     | 151 |
| Ct          | A     | 0.883     | 1.031       | 0.559   | 54.23 | 0.912    | 0.108     | 3.080     | 149 |
| (ng/mL)     | B     | 0.909     | 1.078       | 0.619   | 57.39 | 0.916    | 0.170     | 3.100     | 151 |
| Parameter   | Trt   | GeoMean   | ArithMean   | SD      | %.13  | Median   | Minimum   | Maximum   | N   |

TLIN = start time for linear regression

LQCT=timeofthelastquantifiableconcentration

R2=coefficient ofdeterminationforregression analysis

Ct = last measurable concentration value at LQCT. This value was used for the extrapolation to infinity.

TreatmentA:Abiraterone500mgfilm-coatedtablets,BatchNo.:RA0258

Treatment B: Zytiga(abiraterone acetate) 500 mg film-coated tablets, Batch No.: IGZSB00

<div style=\"page-break-after: always\"></div>

Table 3 : Statistical analysis for abiraterone (ln-transformed values) (Study No. 19-652)

Table 2-1 Summary of Study Results Based on Plasma Abiraterone Levels

| Based onLog-transformedData                                                                               | Based onLog-transformedData                                                                               | Based onLog-transformedData                                                                               | Based onLog-transformedData                                                                               | Based onLog-transformedData                                                                               | Based onLog-transformedData                                                                               | Based onLog-transformedData                                                                               | Based onLog-transformedData                                                                               | Based onLog-transformedData                                                                               |
|-----------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------|
| Parameter                                                                                                 | Trt                                                                                                       | n                                                                                                         | ArithmeticMean (CV%)                                                                                      | GeometricMeanContrast                                                                                     |                                                                                                           | Ratio (%)                                                                                                 | 90%ConfidenceIntra-Sbj Interval                                                                           | (%)4)                                                                                                     |
| AUCt (hr*ng/mL)                                                                                           | A1                                                                                                        | 101                                                                                                       | 347.413 (58)                                                                                              | 304.632                                                                                                   | A vs B                                                                                                    | 96.67                                                                                                     | 91.17 -102.50                                                                                             | 30                                                                                                        |
|                                                                                                           | A2                                                                                                        | 48                                                                                                        | 376.312 (60)                                                                                              |                                                                                                           |                                                                                                           |                                                                                                           |                                                                                                           |                                                                                                           |
|                                                                                                           | B1                                                                                                        | 100                                                                                                       | 367.550 (62)                                                                                              | 315.125                                                                                                   |                                                                                                           |                                                                                                           |                                                                                                           |                                                                                                           |
|                                                                                                           | B2                                                                                                        | 51                                                                                                        | 399.181 (57)                                                                                              |                                                                                                           |                                                                                                           |                                                                                                           |                                                                                                           |                                                                                                           |
| AUCimf (hr*ng/mL)                                                                                         | A1                                                                                                        | 98                                                                                                        | 374.551 (57)                                                                                              | 329.694                                                                                                   | A vs B                                                                                                    | 95.76                                                                                                     | 90.57 -101.24                                                                                             | 28                                                                                                        |
|                                                                                                           | A2                                                                                                        | 48                                                                                                        | 403.028 (58)                                                                                              |                                                                                                           |                                                                                                           |                                                                                                           |                                                                                                           |                                                                                                           |
|                                                                                                           | B1                                                                                                        | 99                                                                                                        | 397.553 (60)                                                                                              | 344.303                                                                                                   |                                                                                                           |                                                                                                           |                                                                                                           |                                                                                                           |
|                                                                                                           | B2                                                                                                        | 50                                                                                                        | 426.548 (57)                                                                                              |                                                                                                           |                                                                                                           |                                                                                                           |                                                                                                           |                                                                                                           |
| Cmax                                                                                                      | A1                                                                                                        | 101                                                                                                       | 69.117 (63)                                                                                               | 57.561                                                                                                    | A vs B                                                                                                    | 96.84                                                                                                     | 90.18 -103.99                                                                                             | 36                                                                                                        |
| (ng/mL)                                                                                                   | A2                                                                                                        | 48                                                                                                        | 69.029 (68)                                                                                               |                                                                                                           |                                                                                                           |                                                                                                           |                                                                                                           |                                                                                                           |
|                                                                                                           | B1                                                                                                        | 100                                                                                                       | 70.238 (59)                                                                                               | 59.438                                                                                                    |                                                                                                           |                                                                                                           |                                                                                                           |                                                                                                           |
|                                                                                                           | B2                                                                                                        | 51                                                                                                        | 77.059 (61)                                                                                               |                                                                                                           |                                                                                                           |                                                                                                           |                                                                                                           |                                                                                                           |
| CV, coefficient of variation; n, number of subjects in statistical dataset; Sbj, subject; Trt, treatment. | CV, coefficient of variation; n, number of subjects in statistical dataset; Sbj, subject; Trt, treatment. | CV, coefficient of variation; n, number of subjects in statistical dataset; Sbj, subject; Trt, treatment. | CV, coefficient of variation; n, number of subjects in statistical dataset; Sbj, subject; Trt, treatment. | CV, coefficient of variation; n, number of subjects in statistical dataset; Sbj, subject; Trt, treatment. | CV, coefficient of variation; n, number of subjects in statistical dataset; Sbj, subject; Trt, treatment. | CV, coefficient of variation; n, number of subjects in statistical dataset; Sbj, subject; Trt, treatment. | CV, coefficient of variation; n, number of subjects in statistical dataset; Sbj, subject; Trt, treatment. | CV, coefficient of variation; n, number of subjects in statistical dataset; Sbj, subject; Trt, treatment. |
| Parameter                                                                                                 | Parameter                                                                                                 | Parameter                                                                                                 | Intra-Subject-within-Reference CV (%) B1 vs.B2                                                            | Intra-Subject-within-Reference CV (%) B1 vs.B2                                                            | Intra-Subject-within-Reference CV (%) B1 vs.B2                                                            | Wider Bioequivalence Range                                                                                | Wider Bioequivalence Range                                                                                | Wider Bioequivalence Range                                                                                |
|                                                                                                           |                                                                                                           |                                                                                                           | 34.8                                                                                                      | 34.8                                                                                                      | 34.8                                                                                                      | 77.34 - 129.30                                                                                            | 77.34 - 129.30                                                                                            | 77.34 - 129.30                                                                                            |
| Treatment A (Test):                                                                                       | Treatment A (Test):                                                                                       | Abiraterone 500 mg film-coated tablets, Batch No.: RA0258                                                 | Abiraterone 500 mg film-coated tablets, Batch No.: RA0258                                                 | Abiraterone 500 mg film-coated tablets, Batch No.: RA0258                                                 | Abiraterone 500 mg film-coated tablets, Batch No.: RA0258                                                 | Abiraterone 500 mg film-coated tablets, Batch No.: RA0258                                                 | Abiraterone 500 mg film-coated tablets, Batch No.: RA0258                                                 | Abiraterone 500 mg film-coated tablets, Batch No.: RA0258                                                 |
| Treatment B                                                                                               | Treatment B                                                                                               | Zytiga? (abiraterone acetate) 500 mg film-coated tablets, Batch No.: IGZSB00                              | Zytiga? (abiraterone acetate) 500 mg film-coated tablets, Batch No.: IGZSB00                              | Zytiga? (abiraterone acetate) 500 mg film-coated tablets, Batch No.: IGZSB00                              | Zytiga? (abiraterone acetate) 500 mg film-coated tablets, Batch No.: IGZSB00                              | Zytiga? (abiraterone acetate) 500 mg film-coated tablets, Batch No.: IGZSB00                              | Zytiga? (abiraterone acetate) 500 mg film-coated tablets, Batch No.: IGZSB00                              | Zytiga? (abiraterone acetate) 500 mg film-coated tablets, Batch No.: IGZSB00                              |

Table 4 : Additional pharmacokinetic data for abiraterone (Study No. 19-652)

| Plasmaconcentrationcurveswhere   | Relatedinformation                                                                              |
|----------------------------------|-------------------------------------------------------------------------------------------------|
| - AUC/AUCinf<0.8                 | Subject period 2, R period 3, T period 1, R Subject period 1, R Subject period 2, R period 2, R |
| - AUC/AUCinf<0.8                 | Subject period 3, R                                                                             |
| - AUC/AUCinf<0.8                 | Subject period 1, R                                                                             |
| - AUC/AUCinf<0.8                 | Subject                                                                                         |
| - AUC/AUCinf<0.8                 | Subject                                                                                         |
| - AUC/AUCinf<0.8                 | Subject period 1, T                                                                             |
| - AUC/AUCinf<0.8                 | Subject                                                                                         |
| Cmax is the first point          | None                                                                                            |
| - Pre-dose sample > 5% Cmax      | None                                                                                            |

<div style=\"page-break-after: always\"></div>

The ANOVA output for treatment/sequence and period effects are presented below:

## AUCt

| Type3TestsofFixedEffects   | Type3TestsofFixedEffects   | Type3TestsofFixedEffects   | Type3TestsofFixedEffects   | Type3TestsofFixedEffects   |
|----------------------------|----------------------------|----------------------------|----------------------------|----------------------------|
| Effect                     | DF                         | NumDen                     | DFFValuePr>F               |                            |
| Sel                        | 1                          | 99                         | 0.11 0.7395                |                            |
| Per                        | 2                          | 196                        | 4.410.0133                 |                            |
| Trt                        |                            | 1196                       | 0.910.3401                 |                            |

## AUCinf

Type3TestsofFixedEffects

| Effect   | NumDen DF   |      | DFFValuePr>F   |
|----------|-------------|------|----------------|
| Sel      | 1           |   99 | 0.02 0.8797    |
| Per      | 2           |  191 | 4.150.0172     |
| Trt      |             | 1191 | 1.66 0.1994    |

## Cmax

| Type3TestsofFixedEffects   | Type3TestsofFixedEffects   | Type3TestsofFixedEffects   | Type3TestsofFixedEffects   | Type3TestsofFixedEffects   |
|----------------------------|----------------------------|----------------------------|----------------------------|----------------------------|
| Effect                     | DF                         | Num Den                    | DFFValuePr>F               |                            |
| Sel                        | 一                          | 99                         | 0.64 0.4242                |                            |
| Per                        |                            | 2196                       | 3.46 0.0333                |                            |
| Trt                        |                            | 1196                       | 0.55 0.4576                |                            |

Based on the above table, treatment effect and sequence effect are found to be statistically insignificant (p-value &gt; 0.05) for ln-transformed pharmacokinetic parameters Cmax, AUC0-t and AUCinf of abiraterone.

Period effect is found to be statistically significant (p-value &lt; 0.05) for ln-transformed pharmacokinetic parameters Cmax, AUCt and AUCinf of abiraterone. A significant period effect could be an indication of an unequal carryover effect. However, there was no sequence effect and even in presence of an unequal carryover effect, the treatment comparison would not be invalidated since it would affect both treatments in the same way. Therefore, it is concluded that these finding does not affect the conclusion of the study.

Mean plasma concentration vs. time profiles (semi-log and linear) of Abiraterone 500 mg test and reference products under fasting conditions are depicted in figure 1.

<div style=\"page-break-after: always\"></div>

Figure 2-1 MeanPlasmaAbirateroneConcentration-TimeProfileinaLinearScale(A1:n=101/A2:n=48/B1:n=100/B2:n=51/Semi-Replicate Measuresfor bothReference[B] and Test [A])

<!-- image -->

Figure 2 Mean Plasma Abiraterone Concentration-Time profile in linear Scale ( A 1:n=101/A2:n=48/B1:n=100/B2:n=51/Semi-Replicate measure s for both Reference (B) and Test (A))

Figure2-2MeanPlasmaAbirateroneConcentration-TimeProfileinaSemi-LogScale（A1:n=101/A2:n=48/B1:n=100/B2:n=51/SemiReplicateMeasuresforbothReference[B]andTest[A])

<!-- image -->

Figure 3 Mean Plasma Abiraterone Concentration-Time profile in Semi-logarithmic Scale (A1:n=101/A2:n=48/B1:n=100/B2:n=51/Semi-Replicate measures for both Reference (B) and Test (A))

As per EMA Guideline for highly variable drugs, the within-subjects variability was estimated using the data from subjects who completed 2 administrations of the reference product. Due to high intrasubject variability of the reference formulation (34.8%), a wider acceptance range of Cmax was applied (77.34% - 129.30%). The request for widened interval was pre-specified in the protocol. The widening of the pharmacokinetic criteria Cmax is in line with the requirements of the Guideline on the Investigation of Bioequivalence (CPMP/EWP/QWP/1401/98 Rev 01/Corr **) section 4.1.10 Highly variable drugs . The geometric least square mean ratio (T/R) was 96.84% for Cmax, which was within the conventional acceptance range of 80.00% to 125.00%. As well as the 90% confidence intervals for the ln-transformed Cmax, AUCinf and AUC0-t are within the acceptance range of 80.00 - 120.00%.

No pre-dose samples larger than 5% Cmax have been reported. The pre-dose concentrations of abiraterone, which was less than 5% of their Cmax were observed for subjects before period-2 or period-3 drug administration at time 0.00h (Period-2: subject: 0.108 ng /mL- test product; subject:

<div style=\"page-break-after: always\"></div>

0.233 ng /mL- reference product and subject: 0.131 ng /mL-reference product and Period-3 subject: 0.130 ng /mL - reference product). Hence those subjects were considered for PK and Statistical analysis as per protocol, which is also in line with the Guideline on the Investigation of Bioequivalence and thus acceptable. Cmax/tmax is not reached at first sample point 0.33 h for any subjects, indicating that the sampling period is adequate. According to Guideline on the investigation of Bioequivalence/CMP/EWP/QWP/1404/98 Rev.1/Corr** , AUC(0-t) should cover at least 80% of AUC(0-∞ ). In this study most of the results demonstrated that the residual area was &lt;20%, except seven subjects (treatment B), (treatment B), (treatment A), (treatment B), (treatment B), (treatment B) and (treatment A+B) exhibit extrapolation higher than 20%. As the number of profiles (8 out of 300 profiles) with extrapolation &gt;20% is less than 20% of the profiles, no question is raised. The statistical methodology using Method B (PROC MIXED procedure) could be acceptable for replicate design according to the EMA`s Q&amp;A document (EMA/582648/2016) as long as all subjects provide data for all treatment periods. The EMA`s Q&amp;A document states: ' Method B using PROC MIXED procedure may be acceptable as long as results obtained with the two methods (Method A and Method B) do not lead to different regulatory decisions. However, in borderline cases and when there are many included subjects who only provide data for a subset of the treatment periods, additional analysis using method A (PROC GLM) might be required '. Therefore, having consider the missing treatment periods for 3 subjects that could cause different results for two approaches (Method A and Method B), the applicant was asked to discuss this issue and if applicable, present additional analysis using method A (PROC GLM). In response to Day 120 LOQ, the applicant submitted the results from Method A (PROC GLM) and compared them with the results of Method B (PROC MIXED). The results of Method A were in agreement with those of Method B. Subject had one missing PK blood sample at 48 hours post dose in period-3 after treatment with the reference product with no missing values affecting the test product. The corresponding abiraterone concentration value was set to be missing. The terminal elimination phase could not be properly characterized for 3 subjects (in period-1, in period-2, in period-2 for treatment A and 2 subjects (in period-3 and in period-1 for treatment B. Hence, no value of elimination parameters was reported for these subjects. The LLOQ of 0.100 ng /mL was sensitive enough to detect levels of 5% of the minimum Cmax (0.471 ng

/mL is 5% of the minimum Cmax=9.420 ng) to exclude the possibility of a relevant carry-over effect.

## Safety data

Safety analysis was carried out on all subjects who were dosed with the investigational product (a single oral dose of either the reference product or test product), which included 102 subjects. No serious adverse events (SAEs) were reported during the conduct of this study. None of the Adverse events (AEs) had a significant impact on the safety of the subjects or on the integrity of the study results. Forty-one (41) subjects (40.2% of subjects dosed) reported a total of 92 AEs. Thirty-one (31) subjects (30.7%) receiving the test product reported 42 AEs, and 27 subjects (26.5%) receiving the reference product reported 50 AEs. Of these, 33 AEs affecting 18 subjects (17.6%) were assessed as treatment related, with 14 subjects (13.9%) reporting 19 treatment-related AEs following administration of the test product and 11 subjects (10.8%) reporting 14 treatment-related AEs following administration of the reference product.

Eighty-eight (88) of the 92 AEs resolved prior to the end of the study.

<div style=\"page-break-after: always\"></div>

The most frequent treatment related AE was headache (11 events affecting 6 subjects [5.9%]). All AEs were mild in severity with the exception of 1 AE (headache) which was moderate in severity. End of Study Twenty-four (24) AEs in 6 subjects (5.9% of subjects dosed) were detected by clinical laboratory tests. The AEs were mild in severity and 20 of these events resolved prior to the end of the study. The resolution of 4 of these AEs is unknown because the subject was lost to follow up. Four (4) of the AEs detected by clinical laboratory tests were assessed as having a possible relationship to the IMP, 2 were assessed as unlikely in relationship to the IMP and the other 18 were assessed as unrelated. Vital Signs, Physical Findings and Other Observations Related to Safety Adverse events detected by vital signs measurements include bradycardia (29 events affecting 21 subjects [20.6%]), ventricular extra systoles (1 event affecting 1 subject [1.0%]) and pyrexia (1 event affecting 1 subject [1.0%]). All AEs detected by vital signs measurements were assessed as unrelated or unlikely in relationship to the IMP. Adverse events detected by ECG measurements include electrocardiogram PR prolongation (6 events affecting 4 subjects [3.9%]) and electrocardiogram QT prolonged (4 events affecting 4 subjects [3.9%]). All 6 events of electrocardiogram PR prolongation were assessed as possibly related to the IMP and all events of electrocardiogram QT prolonged were assessed as possibly related to the IMP. A physical examination detected 1 AE (musculoskeletal stiffness) affecting 1 subject (1.0%). The AE

was mild in severity, assessed as unrelated to the IMP, and resolved prior to the end of the study.

## Conclusions

Based on the presented bioequivalence study 19-652, Abiraterone acetate Krka 500 mg film-coated tablets MAH: KRKA, d.d., Novo mesto, SLOVENIA, EU, is considered bioequivalent with Zytiga (Abiraterone) 500 mg film-coated tablets MAH: Janssen-Cilag International NV, Belgium, EU..

## 2.4.3. Pharmacodynamics

No new pharmacodynamic studies were presented and no such studies are required for this application.

## Additional Data

The applicant presented synopsis of pilot bioavailability study ( No.: 19-624 ) of Abiraterone 500 mg film-coated tablets as supportive data. Pilot study (No.: 19-624) Study title: Single Dose Crossover Comparative Bioavailability Pilot Study of Abiraterone 500 mg FilmCoated Tablets in Healthy Male Subjects Under Fasting Conditions Study Initiation Date: 2019/05/22 Study Completion Date: 2019/07/25 Objectives: The objective of this study was to evaluate the pharmacokinetics (PK) of four different formulations of abiraterone acetate after a single oral dose under fasting conditions.

<div style=\"page-break-after: always\"></div>

Test-1 For the Test-1 (abiraterone 500 mg film-coated tablets, Batch number RA0236, MAH: KRKA, d.d., Novo mesto, SLOVENIA, EU) versus Reference (Zytiga® [abiraterone acetate] 500 mg film-coated tablets, Janssen-Cilag SpA, Italy, EU) comparison, the resulting Test-1 to Reference ratio of geometric leastsquares means (Lsmeans) for the Cmax and AUC0-T were 122.14% and 114.63%, respectively. Time to reach peak exposure (median Tmax) was comparable for both products. Test-2 For the Test-2 (abiraterone 500 mg film-coated tablets, Batch number RA0237, MAH: KRKA, d.d., Novo mesto, SLOVENIA, EU) versus Reference (Zytiga® [abiraterone acetate] 500 mg film-coated tablets, Janssen-Cilag SpA, Italy, EU) comparison, the resulting Test-2 to Reference ratio of geometric LSmeans for the Cmax and AUC0-T were 127.26% and 124.75%, respectively. Median Tmax was comparable for both products. Test-3 For the Test-3 (abiraterone 500 mg film-coated tablets, Batch number RA0239, MAH: KRKA, d.d., Novo mesto, SLOVENIA, EU) versus Reference (Zytiga® [abiraterone acetate] 500 mg film-coated tablets, Janssen-Cilag SpA, Italy, EU) comparison, the resulting Test-3 to Reference ratio of geometric LSmeans for the Cmax and AUC0-T were 93.76% and 93.26%, respectively. The Test-3 formulation showed comparable results to the reference with the mean Cmax and the overall AUC within 7% of the reference product and the Test-3/Reference ratios of geometric LSmeans and the 90% CIs of Cmax and AUC0-T were within the 80.00 to 125.00 % range of bioequivalence. Median Tmax was also comparable for both products. Overall, out of the three test formulations, Test-3 formulation showed comparable PKs to the Reference formulation. Results:

<div style=\"page-break-after: always\"></div>

## Test-1

## PharmacokineticParameters

Abiraterone

| PARAMETER         | TEST-1 (n=46)b   | TEST-1 (n=46)b   | REFERENCE (n=46)b   | REFERENCE (n=46)b   |
|-------------------|------------------|------------------|---------------------|---------------------|
|                   | MEAN             | C.V. (%)         | MEAN                | C.V. (%)            |
| Cmx (ng/mL)       | 93.160           | (79.4)           | 74.824              | (56.0)              |
| Tmax (hours)a     | 2.67             | (1.00-6.02)      | 2.33                | (0.67-6.00)         |
| AUCo.r (ng-h/mL)  | 485.578          | (55.9)           | 426.904             | (51.5)              |
| AUCo.- (ng:h/mL)  | 505.795          | (54.8)           | 445.849             | (50.6)              |
| Residual Area (%) | 4.64             | (89.6)           | 4.78                | (63.6)              |
| z (hours)         | 0.0538           | (26.3)           | 0.0513              | (23.4)              |
| Thalf (hours)     | 13.87            | (29.8)           | 14.27               | (24.2)              |

| INTRA- PARAMETER SUBJECT C.V. (%)   | GEOMETRIC LSMEANS*   | GEOMETRIC LSMEANS*   | RATIO (%)   | 90%CONFIDENCE LIMITS (%)   | 90%CONFIDENCE LIMITS (%)   |
|-------------------------------------|----------------------|----------------------|-------------|----------------------------|----------------------------|
| INTRA- PARAMETER SUBJECT C.V. (%)   | TEST-1 (n=46)b       | REFERENCE (n=46)b    | RATIO (%)   | LOWER                      | UPPER                      |
| 45.2                                | 75.539               | 61.847               | 122.14      | 104.97                     | 142.11                     |
| 31.6                                | 420.467              | 366.795              | 114.63      | 102.73                     | 127.91                     |

## Test-2

## PharmacokineticParameters

Abiraterone

| PARAMETER         | TEST-2 (n=47)b   | TEST-2 (n=47)b   | REFERENCE (n=47)b   | REFERENCE (n=47)b   |
|-------------------|------------------|------------------|---------------------|---------------------|
|                   | MEAN             | C.V. (%)         | MEAN                | C.V. (%)            |
| Cmx (ng/mL)       | 95.584           | (63.6)           | 76.530              | (56.3)              |
| Tmx (hours)a      | 2.33             | (1.00-9.00)      | 2.33                | (0.67-6.00)         |
| AUCo.T (ng-h/mL)  | 533.545          | (50.6)           | 430.989             | (50.8)              |
| AUCo-∞ (ng:h/mL)  | 552.746          | (49.8)           | 450.059             | (50.0)              |
| Residual Area (%) | 4.14             | (79.0)           | 4.76                | (63.2)              |
| z (hours1)        | 0.0549           | (23.1)           | 0.0512              | (23.2)              |
| Thalf (hours)     | 13.32            | (24.2)           | 14.29               | (23.9)              |

| PARAMETER   | INTRA- SUBJECT C.V. (%)   | GEOMETRIC LSMEANS?   | GEOMETRIC LSMEANS?   | RATIO (%)   | 90% CONFIDENCE LIMITS (%)   | 90% CONFIDENCE LIMITS (%)   |
|-------------|---------------------------|----------------------|----------------------|-------------|-----------------------------|-----------------------------|
| PARAMETER   | INTRA- SUBJECT C.V. (%)   | TEST-2 (n=47)b       | REFERENCE (n=47)b    | RATIO (%)   | LOWER                       | UPPER                       |
| Cmmx        | 34.1                      | 80.592               | 63.327               | 127.26      | 113.43                      | 142.79                      |
| AUCo-T      | 26.0                      | 464.238              | 372.136              | 124.75      | 114.06                      | 136.44                      |

<div style=\"page-break-after: always\"></div>

Test-3 PharmacokineticParameters

Abiraterone

| PARAMETER         | TEST-3 (n=46)b   | TEST-3 (n=46)b   | REFERENCE (n=46)b   | REFERENCE (n=46)b   |
|-------------------|------------------|------------------|---------------------|---------------------|
|                   | MEAN             | C.V. (%)         | MEAN                | C.V. (%)            |
| Cmx (ng/mL)       | 70.103           | (57.7)           | 74.824              | (56.0)              |
| Tmax (hours)a     | 2.50             | (1.00-6.05)      | 2.33                | (0.67-6.00)         |
| AUCo.-T (ng:h/mL) | 397.478          | (52.4)           | 426.904             | (51.5)              |
| AUCo-∞ (ng-h/mL)  | 413.861          | (51.8)           | 445.849             | (50.6)              |
| Residual Area (%) | 4.52             | (68.5)           | 4.78                | (63.6)              |
| z (hours')        | 0.0535           | (23.4)           | 0.0513              | (23.4)              |
| Thalf(hours)      | 13.77            | (27.5)           | 14.27               | (24.2)              |

|           | INTRA-           | GEOMETRIC LSMEANSa   | GEOMETRIC LSMEANSa   | RATI0 (%)   | 90% CONFIDENCE LIMITS (%)   | 90% CONFIDENCE LIMITS (%)   |
|-----------|------------------|----------------------|----------------------|-------------|-----------------------------|-----------------------------|
| PARAMETER | SUBJECT C.V. (%) | TEST-3 (m=46)b       | REFERENCE (n=46)b    | RATI0 (%)   | LOWER                       | UPPER                       |
| Cmax      | 33.0             | 57.985               | 61.847               | 93.76       | 83.76                       | 104.94                      |
| AUCo-T    | 25.7             | 342.078              | 366.795              | 93.26       | 85.24                       | 102.03                      |

## 2.4.4. Post marketing experience

No post-marketing data are available. The medicinal product has not been marketed in any country.

## 2.4.5. Discussion on clinical aspects

This application concerns a centralised procedure for the generic Abiraterone acetate Krka 500 mg film-coated tablets with abiraterone acetate as active substance. Essential similarity is claimed to Zytiga containing abiraterone acetate, Janssen-Cilag International N.V., Belgium approved via centralised procedure since 5th of September 2011 (EU/1/11/714/002-003).

Abiraterone is a well-known active substance with established efficacy and tolerability.

A clinical overview has been provided, which is based on up-to-date and adequate scientific literature.

To support the application, the applicant has submitted one pivotal bioequivalence study (No.: 19652), (fasting) and synopsis of pilot bioavailability study (No.: 19-624) as supportive study (fasting). The results of the pilot study were in agreement with those of the pivotal study. Since batch size used in the pilot study (No.: 19-624) is not representative, bioequivalence of the to-be-marketed formulation is based solely on pivotal bioequivalence study.

The pivotal study (No.: 19-652) was designed as an open-label, single-dose, randomized, three-period, two-treatment, two-sequence, cross-over, semi-replicate study to evaluate the bioequivalence of abiraterone in healthy, non-smoking, male subjects under fasted conditions with a washout period of 7 days between drug administrations.

Abiraterone can be considered as a highly variable drug, therefore a replicate design was more appropriate to assess within-subject variability. The study design employed (as a randomized fasting single dose semi replicate design 3-period cross-over) is thus considered appropriate for the evaluation of highly variable drug products and therefore acceptable. The semi-replicate design employed is appropriate for the bioequivalence study of highly variable drug products according to the requirements of the Guideline on the Investigation of Bioequivalence (CPMP/EWP/QWP/1401/98 Rev 01/Corr **). Overall design of this study is acceptable and in line with pharmacokinetic properties of abiraterone. Data regarding the test and reference products were adequate. The population studied is considered appropriate and the main inclusion and exclusion criteria are in line with the requirements of the Guideline on the investigation of Bioequivalence (CPMP/EWP/QWP/1401/98 Rev 01). Only male subjects were included in the study since abiraterone is contraindicated in women who are or may potentially be pregnant due to safety concerns. The sampling periods are acceptable upon review of the graphs with sample time points around Tmax (approximately 2 hours) and with an adequate wash-out period at greater than five times the half-life (approximately 15 hours). Protocol deviations listed in the report were considered minor and do not have a negative effect of the study results. An updated section 16.2.2. including deviation for one subject's missing blood samples has been provided and considered acceptable. The concomitant medication taken by one subject was accounted for in the bioanalytical method. As the parent compound, abiraterone acetate, is almost immediately metabolised after oral administration hence, the demonstration of bioequivalence based on the active metabolite, abiraterone is acceptable. The Analytical method (liquid chromatographic tandem mass spectrometric method) used for the determination of abiraterone in human plasma has been adequately validated. Pre-study and in-study validations were performed according to the requirements of the EMA Guideline on bioanalytical method validation (EMEA/CHMP/EWP/192217/09). The pharmacokinetic variables chosen for the study are adequate. The sampling schedule provides adequate estimation of Cmax. No Cmax was observed in the first time point and no pre-dose samples larger than 5% Cmax have been reported. The statistical methodology using Method B (PROC MIXED procedure) could be acceptable for replicate design according to the EMA`s Q&amp;A document (EMA/582648/2016) as long as all subjects provide data for all treatment periods. Therefore, having consider the missing treatment periods for 3 subjects that could cause different results for two approaches (Method A and Method B), results from Method A (PROC GLM) were compared with the results of Method B (PROC MIXED). The results of Method A were in agreement with those of Method B. According to EMA Guideline on the investigation of Bioequivalence/CMP/EWP/QWP/1404/98 Rev.1/Corr**, AUC0-t should cover at least 80% of AUCinf. In this pivotal study, they are only 8 out of 300 profiles with extrapolation &gt;20% (seven subjects  (treatment B), (treatment B), (treatment A), (treatment B), (treatment B), (treatment B) and (treatment A+B)). The number of profiles with extrapolation &gt;20% is less than 20% of the profiles. One Subject had one missing PK blood sample at 48 hours post dose in period-3 after treatment with the reference product with no missing values affecting the test product. The corresponding abiraterone concentration value was set to be missing. Based on possible high intra-subject variability in abiraterone absorption a wider acceptance range of Cmax (77.34% - 129.30%) was proposed. As the request for wider acceptance interval was

<div style=\"page-break-after: always\"></div>

prospectively specified in the study protocol and study designed accordingly (i.e., semi replicate 3period crossover design), the widening of acceptance criteria for Cmax was considered acceptable. This complies with the requirements of the Guideline on the Investigation of Bioequivalence (CPMP/EWP/QWP/1401/98 Rev 01/Corr **) section 4.1.10 Highly variable drugs. The geometric least square mean ratio (T/R) was 96.84% for Cmax, which was within the conventional acceptance range of 80.00% to 125.00%. As well as the 90% confidence intervals for the ln-transformed Cmax, AUCinf and AUC0-t were within the acceptance range of 80.00 - 120.00%.

Safety evaluation performed for study (No.: 19-652) demonstrated that the test and the reference products were relatively well tolerated by healthy subjects, as a single dose (500 mg tablets) administration. None of the AEs had a significant impact on the safety of the subjects. No new safety concerns related to the administered formulations were noted during the conduct of the study.

## 2.4.6. Conclusions on clinical aspects

Based on the presented bioequivalence study 19-652, Abiraterone acetate Krka 500mg film-coated tablets MAH: KRKA, d.d., Novo mesto, SLOVENIA, EU is considered bioequivalent with Zytiga (Abiraterone) 500mg film-coated tablets MAH: Janssen-Cilag International NV, Belgium, EU.

## 2.5. Risk management plan

## Safety concerns

Table SVIII.1: Summary of safety concern

| Summary of safety concerns   | Summary of safety concerns                                                                                                                                                                                                                                                                                                                                                                                                                                              |
|------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Important identified risks   | • Hepatotoxicity • Cardiac disorders • Osteoporosis including osteoporosis-related fractures • Rhabdomyolysis/Myopathy • Allergic alveolitis • Increased exposure with food                                                                                                                                                                                                                                                                                             |
| Important potential risks    | • Anaemia • Cataract • Drug-drug interaction (CYP2D6)                                                                                                                                                                                                                                                                                                                                                                                                                   |
| Missing information          | • Use in patients with active or symptomatic viral hepatitis • Use in patients with moderate/severe hepatic impairment and chronic liver disease • Use in patients with severe renal impairment • Use in patients with heart disease as evidenced by myocardial infarction, or arterial thrombotic events in the past 6 months, severe or unstable angina, or New York Heart Association Class III or IV heart disease or cardiac ejection fraction measurement of <50% |

<div style=\"page-break-after: always\"></div>

## Pharmacovigilance plan

There are no on-going or planned additional pharmacovigilance activities.

## Risk minimisation measures

The safety information in the proposed product information is aligned to the reference medicinal product.

## Conclusion

The CHMP and PRAC considered that the risk management plan version 0.1 is acceptable.

## 2.6. Pharmacovigilance

## Pharmacovigilance system

The CHMP considered that the pharmacovigilance system summary submitted by the applicant fulfils the requirements of Article 8(3) of Directive 2001/83/EC.

## Periodic Safety Update Reports submission requirements

The requirements for submission of periodic safety update reports for this medicinal product are set out in the list of Union reference dates (EURD list) provided for under Article 107c(7) of Directive 2001/83/EC and any subsequent updates published on the European medicines web-portal.

## 2.7. Product information

## 2.7.1. User consultation

The applicant provided the bridging report with the comparison of the contents with the Product Leaflet (PL) of reference product Zytiga (EMEA/H/C/002321), and proof of the user testing of the reference product PL (i.e. EPAR).Considering that both Parent and Daughter PLs are sufficiently similar to justify the bridging,the Bridging report is acceptable.

## 3. Benefit-risk balance

This application concerns a generic version of Abiraterone Krka 500 mg film-coated tablets. The reference product Zytiga is indicated for metastatic prostate cancer. No nonclinical studies have been provided for this application but an adequate summary of the available nonclinical information for the active substance was presented and considered sufficient. From a clinical perspective, this application does not contain new data on the pharmacokinetics and pharmacodynamics as well as the efficacy and safety of the active substance; the applicant's clinical overview on these clinical aspects based on information from published literature was considered sufficient.

The bioequivalence study forms the pivotal basis with an open-label, single-dose, randomized, threeperiod, two-treatment, two-sequence, cross-over, semi-replicate study healthy, non-smoking, male subjects under fasted conditions with a washout period of 7 days between drug administrations. The study design was considered adequate to evaluate the bioequivalence of this formulation and was in line with the respective European requirements. Choice of dose, sampling points, overall sampling time as well as wash-out period were adequate. The analytical method was validated. Pharmacokinetic and statistical methods applied were adequate.

<div style=\"page-break-after: always\"></div>

The test formulation of Abiraterone Krka met the protocol-defined criteria for bioequivalence when compared with the Zytiga. The geometric least square mean ratio (T/R) was 96.84% for Cmax, which was within the conventional acceptance range of 80.00% to 125.00%. The 90% confidence intervals for the ln-transformed Cmax, AUCinf and AUC0-t are within the acceptance range of 80.00 - 120.00%. Bioequivalence of the two formulations was demonstrated.

A benefit/risk ratio comparable to the reference product can therefore be concluded.

The CHMP, having considered the data submitted in the application and available on the chosen reference medicinal product, is of the opinion that no additional risk minimisation activities are required beyond those included in the product information.

## 4. Recommendation

Based on the CHMP review of data on quality, safety and efficacy, the CHMP considers by consensus that the benefit-risk balance of Abiraterone KRKA is favourable in the following indication:

Abiraterone Krka is indicated with prednisone or prednisolone for:

- the treatment of newly diagnosed high risk metastatic hormone sensitive prostate cancer (mHSPC) in adult men in combination with androgen deprivation therapy (ADT)
- the treatment of metastatic castration resistant prostate cancer (mCRPC) in adult men who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicated
- the treatment of mCRPC in adult men whose disease has progressed on or after a docetaxel-based chemotherapy regimen.

The CHMP therefore recommends the granting of the marketing authorisation subject to the following conditions:

## Conditions or restrictions regarding supply and use

Medicinal product subject to medical prescription (See Annex I: Summary of Product Characteristics, section 4.2).

## Other conditions and requirements of the marketing authorisation

## Periodic Safety Update Reports

The requirements for submission of periodic safety update reports for this medicinal product are set out in the list of Union reference dates (EURD list) provided for under Article 107c(7) of Directive 2001/83/EC and any subsequent updates published on the European medicines web-portal.

<div style=\"page-break-after: always\"></div>

## Conditions or restrictions with regard to the safe and effective use of the medicinal product

## Risk Management Plan (RMP)

The MAH shall perform the required pharmacovigilance activities and interventions detailed in the agreed RMP presented in Module 1.8.2 of the Marketing authorisation and any agreed subsequent updates of the RMP.

An updated RMP should be submitted:

- At the request of the European Medicines Agency;
- Whenever the risk management system is modified, especially as the result of new information being received that may lead to a significant change to the benefit/risk profile or as the result of an important (pharmacovigilance or risk minimisation) milestone being reached.